Abstract: The present invention concerns compositions and methods for regulating or determining fertility in humans and animals. In various embodiments of the invention, LOX and other related enzymes can be used as fertility markers, contraceptive agents, or means of treating infertility. LOX may be detected in accordance with the invention in vitro or in vivo.

Abstract: An example method for detecting an analyte in a sample of a bodily fluid comprises the steps of exposing the bodily fluid sample to electromagnetic energy to cause a thermoelastic expansion in the analyte, and detecting a photoacoustic signal in the sample that results from the thermoelastic expansion.

Abstract: The perinuclear theca 32 (PT32) protein is disclosed and shown to interact with tyrosine kinase c-Yes. PT32, c-Yes, fragments thereof, and molecules that bind thereto can be used in methods of enhancing fertility, treating or diagnosing diminished fertility and abnormal spermiogenesis, in providing contraception, and in identifying contraceptive and fertility-enhancing agents. Transgenic, non-human animals also are disclosed.

Abstract: The perinuclear theca 32 (PT32) protein is disclosed and shown to interact with tyrosine kinase c-Yes. PT32, c-Yes, fragments thereof, and molecules that bind thereto can be used in methods of enhancing fertility, treating or diagnosing diminished fertility and abnormal spermiogenesis, in providing contraception, and in identifying contraceptive and fertility-enhancing agents. Transgenic, non-human animals also are disclosed.

Abstract: The present invention concerns compositions and methods for evaluating fertility in humans and animals. The invention may also be used to identify reproductive cancers such as testicular cancer. In various embodiments of the invention, an Sptrx-3 enzyme is used as a fertility marker. Sptrx-3 may be detected in accordance with the invention in vitro or in vivo.

Abstract: The perinuclear theca 32 (PT32) protein is disclosed and shown to interact with tyrosine kinase c-Yes. PT32, c-Yes, fragments thereof, and molecules that bind thereto can be used in methods of enhancing fertility, treating or diagnosing diminished fertility and abnormal spermiogenesis, in providing contraception, and in identifying contraceptive and fertility-enhancing agents. Transgenic, non-human animals also are disclosed.

Abstract: The present invention concerns compositions and methods for regulating or determining fertility in humans and animals. In various embodiments of the invention, LOX and other related enzymes can be used as fertility markers, contraceptive agents, or means of treating infertility. LOX may be detected in accordance with the invention in vitro or in vivo.

Abstract: The present invention concerns the use of compositions and methods of regulating or evaluating fertility in an animal, in particular a mammal. In various embodiments of the invention, methods of contraception include inhibiting proteasome activity of a gamete, in particular spermatozoon. Proteasomal activity may be inhibited in vitro or in vivo. Inhibitors of the proteasome pathway include, but are not limited to small molecules, peptides, polypeptides (e.g., antibodies and the like) and affinity reagents that bind various components of the proteasome pathway (e.g., aptamers, etc.). In some embodiments, the activity of the proteasome pathway or the activity of a component in the proteasome pathway is inhibited by antibodies that bind and inhibit one or more components of the proteasome pathway.

Abstract: The present invention relates to male infertility, and in particular to assays for predicting fertility in animals including human and bovines. In some embodiments, semen samples are evaluated by measuring the amount of ubiquitin in the sample, and in particular by measuring the extent of ubiquitination spermatozoa. Increased levels of ubiquitination in a sample are correlated with lower fertility. Ubiquitination may be assayed by several methods, including immunocytochemical measurement, ELISA, and flow cytometry.

Abstract: The present invention relates to male infertility, and in particular to assays for predicting fertility in animals including human and bovines. In some embodiments, semen samples are evaluated by measuring the amount of ubiquitin in the sample, and in particular by measuring the extent of ubiquitination spermatozoa. Increased levels of ubiquitination in a sample are correlated with lower fertility. Ubiquitination may be assayed by several methods, including immunocytochemical measurement, ELISA, and flow cytometry.

Abstract: The present invention relates to male infertility, and in particular to assays for predicting fertility in animals including human and bovines. In some embodiments, semen samples are evaluated by measuring the amount of ubiquitin in the sample, and in particular by measuring the extent of ubiquitination spermatozoa. Increased levels of ubiquitination in a sample are correlated with lower fertility. Ubiquitination may be assayed by several methods, including immunocytochemical measurement, ELISA, and flow cytometry.